Publications

Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.

Search

Tag
Author
Journal
Year

Exercise effects on cognitive functioning in young adults with first-episode psychosis: FitForLife.

Authors: Ekblom Ö, Firth J, Forsell Y, Hallgren M, Schembri A, Skott M

Journal: Psychological Medicine

DOI: 10.1017/S0033291718001022

Year Published: 2018

BACKGROUND: Exercise has mood-enhancing effects and can improve cognitive functioning, but the effects in first-episode psychosis (FEP) remain understudied. We examined the feasibility and cognitive effects of exercise in FEP. METHOD: Multi-center, open-label intervention study. Ninety-one outpatients with FEP (mean age = 30 years, 65% male) received usual care plus a 12-week supervised circuit-training program, […]

Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia.

Authors: Chen CH, Chen CK, Cheng WJ, Huang MC, Krystal JH, Pietrzak RH, Xu K

Journal: Schizophrenia Research

DOI: 10.1016/j.schres.2018.02.049

Year Published: 2018

BACKGROUND: Ketamine has been used to probe the biology of psychosis and cognitive dysfunction in humans. High levels of ketamine abuse are associated with persisting psychosis (KPP) in a minority of users. However, relatively little is known about cognitive function among KPP patients and whether the cognitive impairments associated with KPP resemble those of schizophrenia […]

Neurocognitive differences between inpatients and outpatients with symptomatically nonremitted schizophrenia: A cross-sectional study

Authors: Junichi Otaki, Yusuke Kurebayashi

Journal: Perspectives in Psychiatric Care

DOI: 10.1111/ppc.12257

Year Published: 2017

Purpose: We aimed to examine whether neurocognition in individuals with nonremitted schizophrenia differed between inpatients and outpatients. Design and methods:We recruited 59 inpatients and 41 patients with nonremitted schizophrenia (assessedwith the Andreason criteria), and neurocognitive functions were compared between both, controlling for demographics, psychiatric symptoms. Findings: Outpatients with nonremitted schizophrenia performed better on tests of […]

Stimulating cognition in schizophrenia: A controlled pilot study of the effects of prefrontal transcranial direct current stimulation upon memory and learning.

Authors: Collier T, Dolan H, Hodsoll J, Joyce D, Orlov ND, Patel S, Rodzinka-Pasko J, Rothwell J, Shergill SS, Tracy DK

Journal: Brain Stimulation

Volume & Issue: 10 & 3

Page No.: 560-566

DOI: 10.1016/j.brs.2016.12.013

Year Published: 2017

BACKGROUND: Schizophrenia is characterized by prominent cognitive deficits, impacting on memory and learning; these are strongly associated with the prefrontal cortex. OBJECTIVE/HYPOTHESIS: To combine two interventions, transcranial direct current stimulation (tDCS) over the prefrontal cortex and cognitive training, to examine change in cognitive performance in patients with schizophrenia. METHODS: A double blind, sham-controlled pilot study […]

Does the Beck Cognitive Insight Scale Predict Response to Cognitive Remediation in Schizophrenia?

Authors: Benoit A, Bherer L, Harvey PO, Lepage M

Journal: Schizophrenia Research and Treatment

Volume & Issue: 2016

DOI: 10.1155/2016/6371856

Year Published: 2016

Cognitive remediation therapy (CRT) has emerged as a viable treatment option for people diagnosed with schizophrenia presenting disabling cognitive deficits. However, it is important to determine which variables can influence response to CRT in order to provide cost-effective treatment. This study’s aim was to explore cognitive insight as a potential predictor of cognitive improvement after […]

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Authors: Abi-Dargham A, Carter CS, Cho RY, Girgis RR, Glass A, Kegeles LS, Lieberman JA, Slifstein M, Thompson JL, Van Snellenberg JX, Wall M

Journal: Journal of Psychopharmacology

Year Published: 2016

BACKGROUND: Evidence from preclinical and human studies indicates the presence of reduced dopamine-1 receptor (D1R) signaling in the cortex, where D1Rs predominate, in patients with schizophrenia (SCZ), which may contribute to their cognitive deficits. Furthermore, studies in nonhuman primates (NHP) have suggested that intermittent administration of low doses of D1R agonists produce long-lasting reversals in […]

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Authors: Beaver JS, Dunbar GC, Dvergsten C, Fleischhacker WW, Hosford DA, Jett JE, Kane J, Keefe RS, Marder SR, Segreti AC, Toler SM, Walling D

Journal: Schizophrenia Bulletin

Year Published: 2015

OBJECTIVES: This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia. METHODS: In 64 sites in the United States, Russia, Ukraine, Hungary, Romania, and Serbia, 477 outpatients (18-65 years; male 62%; 55% tobacco users) with schizophrenia, treated with a new-generation […]

Calibration and cross-validation of MCCB and CogState in schizophrenia.

Authors: Applegate E, Collier T, Drake RJ, Emsley R, Kapur S, Lees J, Lewis S, Lopez-Lopez C, Michalopoulou P, Pandina GJ

Journal: Psychopharmacology

Year Published: 2015

RATIONALE: Cognitive impairment associated with schizophrenia is a key predictor of functional outcomes. The FDA-accepted MATRICS Consensus Cognitive Battery (MCCB) is held to be the gold standard measure but there are concerns about its ease of administration, reliance on language causing problems with translation and possible practice effects. The CogState Schizophrenia Battery (SB) is suggested […]

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Authors: Hasegawa T, Hashimoto K, Hashimoto T, Iyo M, Kanahara N, Oda Y, Sasaki T, Shiina A, Yoshida T

Journal: Clinical Psychopharmacology and Neuroscience

Volume & Issue: 13 & 1

Page No.: 62-7

DOI: 10.9758/cpn.2015.13.1.62

Year Published: 2015

OBJECTIVE: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated […]

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Authors: Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Grove RA, Horrigan JP, Jarskog LF, Kantrowitz JT, Keefe RS, Keshavan MS, Laurelle M, Lieberman JA, Lowy MT, Marder SR, Maruff P, McMahon RP, Peykamian MA, Seidman LJ

Journal: Schizophrenia Research

DOI: 10.1016/j.schres.2015.01.041.

Year Published: 2015

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, […]

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Authors: Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Grove RA, Horrigan JP, Jarskog LF, Kantrowitz JT, Keefe RS, Keshavan MS, Laurelle M, Lieberman JA, Lowy MT, Marder SR, Maruff P, McMahon RP, Peykamian MA, Seidman LJ

Journal: Schizophrenia Research

DOI: 10.1016/j.schres.2015.01.041.

Year Published: 2015

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, […]

Anterior cingulate activation during Stroop task performance: a PET to MRI coregistration study of individual patients with schizophrenia.

Authors: Crowe SF, Egan GF, Maruff P, Pantelis C, Pipingas A, Stuart GW, Tochon-Danguy HJ, Velakoulis D, Wood SJ, Yücel M

Journal: The American Journal of Psychiatry

Volume & Issue: 159

Page No.: 251-4

Year Published: 2002

OBJECTIVE: The authors used single-subject functional imaging analyses to 1) corroborate the findings of anterior cingulate hypoperfusion during an attentional task in schizophrenia and 2) examine whether anterior cingulate activation is associated with underlying morphology. METHOD: Five healthy subjects and six patients with schizophrenia underwent positron emission tomography scanning while they performed the Stroop task. […]

Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder.

Authors: Goldman D, Hodgkinson CA, Jaeger J, Kane JM, Lipsky RH, Malhotra AK, Persaud S

Journal: American Journal of Human Genetics

Volume & Issue: 75 & 5

Page No.: 862-72

Year Published: 2004

Schizophrenia, schizoaffective disorder, and bipolar disorder are common psychiatric disorders with high heritabilities and variable phenotypes. The Disrupted in Schizophrenia 1 (DISC1) gene, on chromosome 1q42, was originally discovered and linked to schizophrenia in a Scottish kindred carrying a balanced translocation that disrupts DISC1 and DISC2. More recently, DISC1 was linked to schizophrenia, broadly defined, […]

Bradyphrenia and bradykinesia both contribute to altered speech in schizophrenia: A quantitative acoustic study.

Authors: Cannizzaro MS, Cohen H, Rappard F, Snyder PJ

Journal: Cognitive and Behavioral Neurology

Volume & Issue: 18 & 4

Page No.: 206-10

Year Published: 2005

OBJECTIVE: To evaluate the relative contributions of motor and cognitive symptoms on speech output in persons with schizophrenia (SZ). BACKGROUND: Studies of speech production in SZ suggest that atypical prosody (eg, pause) is related to clinical symptoms manifest in flat affect and alogia. Others have suggested that a more general motor slowing, bradykinesia, leads to […]

Does atypical antipsychotic medication improve executive function in schizophrenia?

Authors: Collie A, Maruff P, Snyder PJ

Journal: The International Journal of Neuropsychopharmacology

Volume & Issue: 9 & 5

Page No.: 629-30

Year Published: 2006

1 2 3 4